Literature DB >> 21793027

Prevention of recurrence after resection of hepatocellular carcinoma: a daunting challenge.

Ronnie T P Poon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21793027     DOI： 10.1002/hep.24569

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  69 in total

1.  A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Ariel Km Chow; Thomas Cc Yau; Lui Ng; Andrew Cy Chu; Wai-Lun Law; Ronnie Tp Poon; Roberta Wc Pang
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients.

Authors:  Lu He; Xinke Zhou; Chen Qu; Yunqiang Tang; Qiong Zhang; Jian Hong
Journal:  Med Oncol       Date:  2013-08-31       Impact factor: 3.064

3.  The Molecular Chaperone Heat Shock Protein 70 Controls Liver Cancer Initiation and Progression by Regulating Adaptive DNA Damage and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways.

Authors:  Wonkyoung Cho; Xiongjie Jin; Junfeng Pang; Yan Wang; Nahid F Mivechi; Demetrius Moskophidis
Journal:  Mol Cell Biol       Date:  2019-04-16       Impact factor: 4.272

4.  Preventive Inhibition of Liver Tumorigenesis by Systemic Activation of Innate Immune Functions.

Authors:  Jin Lee; Rui Liao; Gaowei Wang; Bi-Huei Yang; Xiaolin Luo; Nissi M Varki; Shuang-Jian Qiu; Bing Ren; Wenxian Fu; Gen-Sheng Feng
Journal:  Cell Rep       Date:  2017-11-14       Impact factor: 9.423

5.  Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma.

Authors:  Soichi Iritani; Kenji Imai; Koji Takai; Tatsunori Hanai; Takayasu Ideta; Tsuneyuki Miyazaki; Atsushi Suetsugu; Makoto Shiraki; Masahito Shimizu; Hisataka Moriwaki
Journal:  J Gastroenterol       Date:  2014-05-10       Impact factor: 7.527

6.  Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.

Authors:  Jiyeon Hyeon; Soomin Ahn; Jae Jun Lee; Dae Hyun Song; Cheol-Keun Park
Journal:  Dig Dis Sci       Date:  2013-03-02       Impact factor: 3.199

7.  Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin.

Authors:  Lihua Min; Yuan Ji; Latifa Bakiri; Zhixin Qiu; Jin Cen; Xiaotao Chen; Lingli Chen; Harald Scheuch; Hai Zheng; Lunxiu Qin; Kurt Zatloukal; Lijian Hui; Erwin F Wagner
Journal:  Nat Cell Biol       Date:  2012-10-07       Impact factor: 28.824

8.  Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence.

Authors:  Chun-Jen Liu; Juliana Chang; Po-Huang Lee; Deng-Yn Lin; Cheng-Chung Wu; Long-Bin Jeng; Yih-Jyh Lin; King-Tong Mok; Wei-Chen Lee; Hong-Zen Yeh; Ming-Chih Ho; Sheng-Shun Yang; Mei-Due Yang; Ming-Chin Yu; Rey-Heng Hu; Cheng-Yuan Peng; Kuan-Lang Lai; Stanley Shi-Chung Chang; Pei-Jer Chen
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Overexpression of annexin A4 indicates poor prognosis and promotes tumor metastasis of hepatocellular carcinoma.

Authors:  Wenwei Chen; Lihong Chen; Zhixiong Cai; Dong Liang; Bixing Zhao; Yongyi Zeng; Xiaolong Liu; Jingfeng Liu
Journal:  Tumour Biol       Date:  2016-01-16

10.  Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.

Authors:  Robert G Gish; Richard S Finn; Jorge A Marrero
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.